ENYO Pharma versterkt zijn managementteam om zijn strategie van internationale groei te ondersteunen
LYON, France–(BUSINESS WIRE)– ENYO Pharma, een biofarmaceutisch bedrijf dat zich momenteel richt op de ontwikkeling van behandelingen tegen virusinfecties, heeft vandaag aangekondigd dat het zijn managementteam versterkt door vier zeer gekwalificeerde experts te benoemen. Zij zijn alle vier experts in de ontwikkeling van medicijnen.
Jacky Vonderscher, directeur van ENYO Pharma lichtte toe, ”We zijn zeer blij dat we deze vier persoonlijkheden, wier grote ervaring en vaardigheden cruciaal zullen zijn in de ondersteuning van onze ontwikkeling, mogen verwelkomen. Deze vier toonaangevende experts zullen bijdragen aan de ontwikkeling van onze bedrijfsstructuur en zullen helpen bij de versnelling van de ontwikkeling van ons belangrijkste project EYP001, een FXR agonist voor de behandeling van het Hepatitis B-virus. Daarnaast zullen ze de ontwikkeling van nieuwe therapeutische aanpakken van andere virussen en andere significante klinische gebieden stimuleren.”
ENYO Pharma Strengthens Its Management Team to Support Its Strategy of International Growth |
|||||
|
LYON, France–(BUSINESS WIRE)– ENYO Pharma, a biopharmaceutical company currently focused on developing treatments for viral infections, has today announced that it is strengthening its management team with the appointment of four highly-qualified experts, all of whom are experts in drug development. Jacky Vonderscher, Chief Executive Officer of ENYO Pharma commented, “We are delighted to welcome these four personalities whose solid experience and established skill sets will be crucial in supporting our development. These four leading experts, will contribute to developing our Corporate structure and help to accelerate the development of our flagship EYP001 project, an FXR agonist for the treatment of the Hepatitis B virus. In addition, they will foster the development of new therapeutic approaches to other viruses and other significant clinical areas.” Annette Clancy, Chairman of the Board of Directors and Independent Director Annette Clancy has more than 30 years of experience in the pharmaceuticals industry, mainly at GlaxoSmithKline (GSK). She held several posts at GSK in the USA and the UK notably in R&D, global marketing and licensing strategy, and commercial development. Until 2008 she was Head of International Transactions and Alliance Management, responsible for delivering innovative partnerships on early-stage drugs, international commercial alliances and mergers and acquisitions. Since then, Annette has concentrated on working with healthcare biotech companies. She is currently the Non-Executive Chairman of three private European companies: ObsEva, Lysogene and ENYO Pharma. Annette is also a Non-Executive Director at SOBI and a Senior Advisor to Frazier Healthcare, a US venture capital group specialising in the healthcare sector. Dr. Timothy M. Wright, Independent Administrator Timothy M. Wright is the Executive Vice-President for Research and Development at Regulus, a Californian Biotech company and until recently, was the Executive Vice President of Translational Sciences at the California Institute for Biomedical Research (Calibr). With degrees in Biology from the University of Delaware and Medicine from John Hopkins University (Rheumatology, Immunology and Molecular Biology), Timothy entered the pharmaceutical industry after a brilliant academic career at John Hopkins and the University of Pittsburgh. Over more than 14 years, initially with Pfizer and then Novartis, Timothy directed early-stage and clinical research programmes. He was Global Head of Development at Novartis in Basel, Switzerland. Timothy has been the Scientific Adviser to several organisations, including the Bill and Melinda Gates Foundation. Dr. Pietro Scalfaro, Chief Medical Officer Pietro Scalfaro is in charge of strategy and operational management of early-stage clinical drug development at ENYO Pharma. He has a wide range experience in this role in the healthcare sector, working notably in infectious diseases (HCV, via the development of Alisporivir), septicaemia, oncology, Alzheimer’s disease and cardio-respiratory diseases. Pietro also set up a Personalised Medicine Business Unit at Debiopharm Group and is involved in Swiss eHealth start-up companies. He is a physician, with a degree from the University of Lausanne, certificates in Paediatrics and Intensive Care, and holds an MBA. Dr. Eric Meldrum, Chief Scientific Officer Eric Meldrum is responsible for the strategy and operational management of pre-clinical drug discovery and development at ENYO Pharma. Eric is a specialist in drug development, having worked for major pharmaceutical groups and biotechnology companies. Before joining ENYO Pharma, he was Chief Scientific Officer at Genkyotex and at 3V Biosciences, where he developed portfolios of NOX-inhibiting molecules and of molecules targeting the replication of respiratory viruses respectively. Prior to this, he was the Director of the Asthma Disease Biology Department at GSK, where he was accountable for the biology associated with more than a dozen drug research and development programmes through to Phase 2 of clinical trials. As part of this new structure, ENYO Pharma has changed its legal form from an SAS company to an SA company. Annette Clancy and Timothy Wright have thus joined the other members of the Board of Directors: Jason Dinges, Jean-Jacques Garaud, Chahra Louafi, Rafaèle Tordjman and Jacky Vonderscher. ENYO Pharma’s technological platform – http://www.enyopharma.com/science/principle/ ENYO Pharma SA – www.enyopharma.com View source version on businesswire.com: http://www.businesswire.com/news/home/20161107006071/en/ Contacts ENYO Pharma |
|||||